Emily Bodnar Analyst Performance

Biotech Equity Research Analyst at HC Wainwright

Emily Bodnar is a stock analyst at HC Wainwright, covering 24 publicly traded companies across a range of sectors. Over the past year, Emily Bodnar has issued 59 stock ratings, including buy and hold recommendations. While full access to Emily Bodnar's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Emily Bodnar's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rating: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 60 Last 3 Years
Buy Recommendations: 88.33% 53 Buy Ratings
Companies Covered: 24 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	88.3%	53 ratings
Hold	11.7%	7 ratings
Sell	0.0%	0 ratings

Out of 60 total stock ratings issued by Emily Bodnar at HC Wainwright, the majority (88.3%) have been Buy recommendations, followed by 11.7% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	24 companies

Emily Bodnar, an analyst at HC Wainwright, currently covers 24 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 24 companies	100.0%

Emily Bodnar of HC Wainwright specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 19 companies	79.2%
MED - DRUGS 3 companies	12.5%
MED INSTRUMENTS 1 company	4.2%
PHARMACEUTICAL PREPARATIONS 1 company	4.2%

About Emily Bodnar

Emily Bodnar is a Vice President of Equity Research at H.C. Wainwright who joined the firm in January 2022. Ms. Bodnar’s research focuses on the Biotechnology and Women’s Healthcare industries. Prior to joining H.C. Wainwright, Ms. Bodnar was a Senior Equity Research Associate at Cantor Fitzgerald assisting in coverage of small/mid and large-cap biotechnology companies. Ms. Bodnar also worked as an Equity Research Associate at Berenberg Capital Markets assisting in coverage of small/mid-cap biotechnology companies. Ms. Bodnar graduated summa cum laude from Binghamton University where she received a Bachelor of Science. Ms. Bodnar has also taken several Biology and Immunology courses from Johns Hopkins University and Rice University.

Follow on LinkedIn

Time Frame

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
AGIO Agios Pharmaceuticals	9/4/2025	Reiterated Rating	$35.90	$56.00	Buy
AGEN Agenus	8/28/2025	Reiterated Rating	$4.54	$23.00	Buy
INKT MiNK Therapeutics	8/15/2025	Upgrade	$15.32	$35.00	Buy
VTVT vTv Therapeutics	8/13/2025	Reiterated Rating	$14.50	$36.00	Buy
FEMY Femasys	8/11/2025	Lower Price Target	$0.85	$8.00	Buy
CNTX Context Therapeutics	8/7/2025	Lower Price Target	$0.70	$4.00	Buy
SABS SAB Biotherapeutics	7/22/2025	Lower Price Target	$2.70	$9.00	Buy
INKT MiNK Therapeutics	7/15/2025	Downgrade	$29.53	$35.00	Neutral
JSPR Jasper Therapeutics	7/7/2025	Lower Price Target	$3.04	$20.00	Buy
NXTC NextCure	7/1/2025	Reiterated Rating	$5.52	$36.00	Buy
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
FEMY Femasys	6/25/2025	Reiterated Rating	$0.95	$12.00	Buy
ACLX Arcellx	6/16/2025	Reiterated Rating	$66.00	$115.00	Buy
FEMY Femasys	6/11/2025	Reiterated Rating	$0.84	$12.00	Buy
AGEN Agenus	6/4/2025	Upgrade	$5.00	$25.00	Buy
SABS SAB Biotherapeutics	5/14/2025	Initiated Coverage	$1.80	$10.00	Buy
AGEN Agenus	5/13/2025	Reiterated Rating	$3.50		Neutral
FEMY Femasys	5/9/2025	Lower Price Target	$1.16	$12.00	Buy
AGEN Agenus	4/30/2025	Reiterated Rating	$3.05		Neutral
OLMA Olema Pharmaceuticals	4/28/2025	Reiterated Rating	$4.91	$30.00	Buy
SANA Sana Biotechnology	4/24/2025	Reiterated Rating	$1.71	$11.00	Buy
BCTX Briacell Therap	4/22/2025	Reiterated Rating	$48.03	$320.00	Buy
RNAZ TransCode Therapeutics	4/16/2025	Lower Price Target	$11.14	$280.00	Buy
VTVT vTv Therapeutics	4/9/2025	Initiated Coverage	$15.80	$36.00	Buy
IOBT IO Biotech	4/1/2025	Reiterated Rating	$1.09	$12.00	Buy
GNLX Genelux	3/31/2025	Reiterated Rating	$3.08	$30.00	Buy
CNTB Connect Biopharma	3/31/2025	Reiterated Rating	$0.68	$8.00	Buy
FEMY Femasys	3/28/2025	Reiterated Rating	$1.34	$15.00	Buy
NKTX Nkarta	3/27/2025	Reiterated Rating	$1.37	$18.00	Buy
IMNN Imunon	3/26/2025	Reiterated Rating	$15.00	$210.00	Buy
ACRV Acrivon Therapeutics	3/26/2025	Lower Price Target	$5.39	$19.00	Buy
ATOS Atossa Genetics	3/26/2025	Reiterated Rating	$0.72	$7.00	Buy
GNLX Genelux	3/25/2025	Reiterated Rating	$3.41	$30.00	Buy
CNTX Context Therapeutics	3/21/2025	Reiterated Rating	$0.77	$5.00	Buy
OLMA Olema Pharmaceuticals	3/19/2025	Reiterated Rating	$4.14	$30.00	Buy
FEMY Femasys	3/19/2025	Boost Price Target	$1.60	$15.00	Buy
AGEN Agenus	3/18/2025	Reiterated Rating	$1.78		Neutral
SANA Sana Biotechnology	3/18/2025	Reiterated Rating	$2.77	$11.00	Buy
INKT MiNK Therapeutics	3/18/2025	Reiterated Rating	$8.06	$35.00	Buy
NXTC NextCure	3/17/2025	Reiterated Rating	$8.45	$36.00	Buy
RNAZ TransCode Therapeutics	3/13/2025	Reiterated Rating	$25.34	$560.00	Buy

FEMY Femasys	3/13/2025	Reiterated Rating	$1.44	$12.00	Buy
ATOS Atossa Genetics	3/12/2025	Reiterated Rating	$0.74	$7.00	Buy
AGEN Agenus	3/12/2025	Reiterated Rating	$2.05		Neutral
OLMA Olema Pharmaceuticals	3/11/2025	Reiterated Rating	$4.25	$30.00	Buy
JSPR Jasper Therapeutics	3/11/2025	Reiterated Rating	$5.14	$40.00	Buy
NXTC NextCure	3/7/2025	Reiterated Rating	$8.55	$36.00	Buy
IOBT IO Biotech	3/5/2025	Reiterated Rating	$0.91	$12.00	Buy
OLMA Olema Pharmaceuticals	3/5/2025	Reiterated Rating	$4.18	$30.00	Buy
FEMY Femasys	2/26/2025	Reiterated Rating	$1.58	$12.00	Buy
INKT MiNK Therapeutics	2/25/2025	Boost Price Target	$10.65	$35.00	Buy
AGIO Agios Pharmaceuticals	2/24/2025	Initiated Coverage	$35.22	$58.00	Buy
FEMY Femasys	2/11/2025	Reiterated Rating	$1.26	$12.00	Buy
RNAZ TransCode Therapeutics	2/6/2025	Reiterated Rating	$321.02	$560.00	Buy
TNYA Tenaya Therapeutics	2/3/2025	Reiterated Rating	$1.05	$18.00	Buy
BCTX Briacell Therap	2/3/2025	Boost Price Target	$50.80	$320.00	Buy
ATOS Atossa Genetics	1/30/2025	Reiterated Rating	$0.86	$7.00	Buy
AGEN Agenus	1/22/2025	Reiterated Rating	$3.83		Neutral
VTYX Ventyx Biosciences	1/14/2025	Reiterated Rating	$1.95		Neutral
JSPR Jasper Therapeutics	1/10/2025	Lower Price Target	$6.99	$40.00	Buy

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.